Lawsuit filed for Investors who lost money with shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)

An investor, who purchased shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), filed a lawsuit over alleged violations of Federal Securities Laws by Brainstorm Cell Therapeutics Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) have certain options and for certain investors are short and strict deadlines running. Deadline: January 2, 2024. NASDAQ: BCLI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

New York based Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
On September 27, 2023, the U.S. Food and Drug Administration ("FDA") issued a briefing document rejecting Brainstorm Cell Therapeutics' experimental ALS drug. rainstorm Cell Therapeutics Inc submitted a biologics license application ("BLA") request in August 2022 and received a refusal to file letter from the FDA in November 2022. Despite this, Brainstorm Cell Therapeutics Inc opted for the regulatory procedure of "filing over protest" and still filed the BLA. The briefing document states, "On initial receipt of the BLA, FDA determined that the submission was scientifically incomplete to demonstrate substantial evidence of effectiveness, and that the manufacturing information was grossly deficient to ensure adequate product quality. Examples of critical information not provided in the BLA submission include missing or inadequate control of materials, validation of methods missing or incomplete, lack of data demonstrating manufacturing consistency, control strategy for prefilled syringe not provided, inadequate manufacturing and testing facility information, and facilities not ready for inspection." In addition, the briefing document states, "[i]n addition to the above clinical and statistical concerns, the review team has substantial concerns about product manufacturing. Those issues have yet to be resolved."

Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) declined from $3.29 per share in May 2023 to as low as $0.16 per on October 03, 2023.

The plaintiff claims that between August 15, 2022 and September 27, 2023, the defendants made materially false and/or misleading statements and/or failed to disclose that Brainstorm Cell downplayed the severity of the Food and Drug Administration's ("FDA") refusal to file letter, that Brainstorm Cell continued to conceal the risks associated with the submission of the biologics license application ("BLA"), and that as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times

Those who purchased shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.